Quick Answer
Viking Therapeutics, Inc. reported Operating Income Loss of -$393.34 million for the year ending 2025.
- Viking Therapeutics, Inc. showed a decrease of -160.6% in Operating Income Loss from 2024 to 2025.
- This data is from Viking Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Viking Therapeutics, Inc.'s Operating Income Loss has declined by 1,576.1%.
- Historical annual values: Fiscal year 2025: -$393.34 million | Fiscal year 2024: -$150.92 million | Fiscal year 2023: -$100.83 million | Fiscal year 2022: -$70.36 million | Fiscal year 2021: -$55.68 million | Fiscal year 2020: -$42.66 million | Fiscal year 2019: -$32.69 million | Fiscal year 2018: -$26.16 million | Fiscal year 2017: -$19.07 million | Fiscal year 2016: -$13.85 million | Fiscal year 2015: -$12.00 million | Fiscal year 2014: -$23.47 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: